| 吴利英,魏 莉,谢婷婷,双 婷,李玲霞.新辅助化疗联合肿瘤细胞减灭术对晚期卵巢癌患者的疗效及对血流动力学参数的影响[J].现代生物医学进展英文版,2018,(19):3657-3660. |
| 新辅助化疗联合肿瘤细胞减灭术对晚期卵巢癌患者的疗效及对血流动力学参数的影响 |
| Clinical Efficacy of Neoadjuvant Chemotherapy Combined with Cytoreductive Surgery in the Treatment of Patients with Advanced Ovarian Cancer and Its Influence on the Blood Flow Parameters |
| Received:March 18, 2018 Revised:April 13, 2018 |
| DOI：10.13241/j.cnki.pmb.2018.19.012 |
| 中文关键词: 卵巢癌 肿瘤细胞减灭术 新辅助化疗 血流参数 |
| 英文关键词: Ovarian carcinoma Cytoreductive surgy Neoadjuvant chemotherapy Blood flow parameter |
| 基金项目:国家自然科学基金项目（81702555） |
|
| Hits: 508 |
| Download times: 225 |
| 中文摘要: |
| 摘要 目的：探讨新辅助化疗联合肿瘤细胞减灭术对晚期卵巢癌患者的疗效及对血流参数的影响。方法：选取2015年1月-2017年6月我院诊治的158例晚期卵巢癌患者，按治疗方法分为对照组、观察组，各79例。对照组使用肿瘤细胞减灭术进行常规卵巢癌治疗，观察组在常规基础上联合新辅助化疗进行治疗。比较两组临床疗效、治疗前后血流动力学参数的变化及不良反应的发生情况。结果：治疗后，观察组化疗的表观缓解率(83.54 %)显著高于对照组(62.03 %)(P<0.05)。两组患者治疗前各血流动力学参数比较差异无统计学意义(P>0.05)，观察组术后1、4、12 w颈动脉收缩期最大流速(peak systolic velocity，PSV)均显著低于对照组(P<0.05)，血管阻力指数(resisitance index，RI)、搏动指数(pulsatility index，PI)均显著高于对照组(P<0.05)。两组患者在治疗期间出现的心脏毒性反应的发生率比较差异无统计学意义(P>0.05)，对照组患者治疗期间骨髓抑制、恶心呕吐、肝脏损伤、肾脏损伤的不良反应程度显著低于观察组(P<0.05)。结论：新辅助化疗联合肿瘤细胞减灭术能够显著提高患者的临床疗效，改善卵巢的血流动力学参数。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical efficacy of neoadjuvant chemotherapy combined with cytoreductive surgery in the treatment of patients with advanced ovarian cancer and its influence on the blood flow parameters. Methods: 158 cases pof patients with advanced ovarian cancer admitted in our hospital from January 2015 to June 2017. All patients were divided into the control group and the observation group according to the treatment methods, 79 cases in each group. The control group was treated with cytoreductive surgery. The observation group was treated with neoadjuvant chemotherapy on a routine basis. The clinical efficacy, changes of blood flow parameters before and after treatment and incidence of adverse reactions were compared between two groups. Results: The apparent response rate (83.54%) of observation group was significantly higher than that in the control group (62.03%) (P<0.05). There was no sig- nificant difference in the blood flow parameters between the two groups before treatment(P>0.05). The PSV of observation group at 1, 4, and 12 weeks postoperation were significantly lower than those of the control group(P<0.05). The RI and PI of observation group were significantly higher than those of the control group(P<0.05). There was no significant difference in the incidence of cardiotoxicity be- tween the two groups during treatment(P>0.05). In the control group, the degree of adverse reactions of myelosuppression, nausea and vomiting, liver injury and renal injury were significantly lower than those in the observation group during the treatment(P<0.05). Conclusion: Neoadjuvant chemotherapy combined with cytoreductive surgery can more effectively improve the clinical efficacy of patients and im- prove the ovarian blood flow parameters than cytoreductive surgery alone. |
|
View Full Text
View/Add Comment Download reader |
| Close |
